Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas

Laryngoscope

Volumn 122, Issue 1, 2012, Pages 174-189

  Jacob, Abraham ^a,b   Oblinger, Janet ^a,b,c   Bush, Matthew L ^a,b,d   Brendel, Victoria ^a,b   Santarelli, Griffin ^e   Chaudhury, Abhik R ^a   Kulp, Samuel ^a   La Perle, Krista M D ^a   Chen, Ching Shih ^a   Chang, Long Sheng ^a,b,c   Welling, D Bradley ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

AKT; apoptosis; AR42; cell cycle arrest; histone deacetylase; histone deacetylase inhibitors; merlin; Neurofibromatosis type 2; vestibular schwannoma

Indexed keywords

AR 42; HISTONE DEACETYLASE INHIBITOR; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ACOUSTIC NEURINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; CELLS, CULTURED; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NEUROMA, ACOUSTIC; PHENYLBUTYRATES;

EID: 84355161485     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.22392     Document Type: Article

References (104)

1. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363: 515-521. (Pubitemid 23186636)
2. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 72: 791-800. (Pubitemid 23093886)
3. Welling DB, Packer MD, Chang LS,. Molecular studies of vestibular schwannomas: a review. Curr Opin Otolaryngol Head Neck Surg 2007; 15: 341-346. (Pubitemid 47373981)
4. Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME,. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 2006; 43: 289-294.
5. Balasubramaniam A, Shannon P, Hodaie M, Laperriere N, Michaels H, Guha A,. Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro Oncol 2007; 9: 447-453.
6. Son EI, Kim IM, Kim SP,. Vestibular schwannoma with malignant transformation: a case report. J Korean Med Sci 2001; 16: 817-821.
7. Levine EM, Becker Y, Boone CW, Eagle H,. Contact inhibition, macromolecular synthesis, and polyribosomes in cultured human diploid fibroblasts. Proc Natl Acad Sci U S A 1965; 53: 350-356.
8. Levine BB,. Studies on delayed hypersensitivity. I. Inferences on the comparative binding affinities of antibodies mediating delayed and immediate hypersensitivity reactions in the guinea pig. J Exp Med 1965; 121: 873-888.
9. Eagle H, Levine EM, Boone CW,. Cellular growth, contact inhibition, and macromolecular synthesis. Science 1965; 148: 665.
10. Evans DG,. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 2009; 4: 16.
11. Eldridge R,. Central neurofibromatosis with bilateral acoustic neuroma. Adv Neurol 1981; 29: 57-65.
12. Curto M, McClatchey AI,. Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. Br J Cancer 2008; 98: 256-262. (Pubitemid 351161230)
13. Maitra S, Kulikauskas RM, Gavilan H, Fehon RG,. The tumor suppressors Merlin and expanded function cooperatively to modulate receptor endocytosis and signaling. Curr Biol 2006; 16: 702-709.
14. Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI,. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol 2007; 177: 893-903. (Pubitemid 46873094)
15. James MF, Beauchamp RL, Manchanda N, Kazlauskas A, Ramesh V,. A NHERF binding site links the betaPDGFR to the cytoskeleton and regulates cell spreading and migration. J Cell Sci 2004; 117: 2951-2961. (Pubitemid 39117670)
16. McClatchey AI, Fehon RG,. Merlin and the ERM proteins-regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol 2009; 19: 198-206.
17. Altomare DA, Testa JR,. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24: 7455-7464. (Pubitemid 41637985)
18. Jacob A, Lee TX, Neff BA, Miller S, Welling B, Chang LS,. Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma. Otol Neurotol 2008; 29: 58-68.
19. Lee TX, Packer MD, Huang J, et al. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. Eur J Cancer 2009; 45: 1709-1720.
20. Hilton DA, Ristic N, Hanemann CO,. Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ. Histopathology 2009; 55: 744-749.
21. Gregoretti IV, Lee YM, Goodson HV,. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004; 338: 17-31. (Pubitemid 38429783)
22. Minucci S, Pelicci PG,. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51. (Pubitemid 43054973)
23. Chen CS,. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 2005; 280: 38879-38887.
24. Bush ML, Oblinger J, Brendel V, et al. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro Oncol 2011; 13: 983-999.
25. Giovannini M, Robanus-Maandag E, van der Valk M, et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 2000; 14: 1617-1630. (Pubitemid 30460911)
26. Drummond DC, Marx C, Guo Z, et al. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res 2005; 11: 3392-3401. (Pubitemid 40627892)
27. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC,. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45: 495-528. (Pubitemid 40261815)
28. Dokmanovic M, Clarke C, Marks PA,. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5: 981-989. (Pubitemid 350080267)
29. Dokmanovic M, Marks PA,. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005; 96: 293-304. (Pubitemid 41437862)
30. Kelly WK, Marks PA,. Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005; 2: 150-157. (Pubitemid 40823166)
31. Xu WS, Parmigiani RB, Marks PA,. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-5552. (Pubitemid 47255934)
32. Sasakawa Y, Naoe Y, Inoue T, et al. Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Lett 2003; 195: 161-168. (Pubitemid 36588965)
33. Sasakawa Y, Naoe Y, Inoue T, et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 2002; 64: 1079-1090. (Pubitemid 35247815)
34. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K,. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003; 101: 3236-3239. (Pubitemid 36858020)
35. Abramova MV, Pospelova TV, Nikulenkov FP, Hollander CM, Fornace AJ Jr, Pospelov VA,. G1/S arrest induced by histone deacetylase inhibitor sodium butyrate in E1A + Ras-transformed cells is mediated through down-regulation of E2F activity and stabilization of beta-catenin. J Biol Chem 2006; 281: 21040-21051. (Pubitemid 44115445)
36. Archer SY, Johnson J, Kim HJ, et al. The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21/WAF-1-dependent mechanism in human colon cancer cells. Am J Physiol Gastrointest Liver Physiol 2005; 289: 696-703.
37. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA,. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 2004; 101: 1241-1246. (Pubitemid 38182673)
38. Han JW, Ahn SH, Kim YK, et al. Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C. J Biol Chem 2001; 276: 42084-42090.
39. Han JW, Ahn SH, Park SH, et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 2000; 60: 6068-6074.
40. Hecker RM, Amstutz RA, Wachtel M, Walter D, Niggli FK, Schafer BW,. p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment. Oncogene 2010; 29: 3942-3952.
41. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005; 280: 26729-26734. (Pubitemid 41040705)
42. Banerji U,. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009; 15: 9-14.
43. Glaser KB,. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 2007; 74: 659-671. (Pubitemid 47096639)
44. Solit DB, Rosen N,. Hsp90: a novel target for cancer therapy. Curr Top Med Chem 2006; 6: 1205-1214. (Pubitemid 44120915)
45. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP,. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115: 727-738. (Pubitemid 38030301)
46. Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ,. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 2008; 22: 1026-1034. (Pubitemid 351689885)
47. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL,. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003; 100: 4389-4394. (Pubitemid 36457739)
48. Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002; 417: 455-458. (Pubitemid 34563539)
49. Matsuyama A, Shimazu T, Sumida Y, et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 2002; 21: 6820-6831. (Pubitemid 36014554)
50. Zhang Y, Li N, Caron C, et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 2003; 22: 1168-1179. (Pubitemid 36313600)
51. Ahn MY, Jung JH, Na YJ, Kim HS,. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol Oncol 2008; 108: 27-33. (Pubitemid 350299431)
52. D'Acunto CW, Carratu A, Rodriquez M, Taddei M, Parente L, Petrella A,. LGP1, A histone deacetylase inhibitor analogue of FR235222, sensitizes promyelocytic leukaemia U937 cells to TRAIL-mediated apoptosis. Anticancer Res 2010; 30: 887-894.
53. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71-76. (Pubitemid 40215840)
54. Kulp SK, Chen CS, Wang DS, Chen CY,. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res 2006; 12: 5199-5206. (Pubitemid 44453349)
55. Shankar S, Srivastava RK,. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 2008; 615: 261-298.
56. Barter MJ, Pybus L, Litherland GJ, et al. HDAC-mediated control of ERK- and PI3K-dependent TGF-beta-induced extracellular matrix-regulating genes. Matrix Biol 2010; 29: 602-612.
57. Kim YK, Seo DW, Kang DW, Lee HY, Han JW, Kim SN,. Involvement of HDAC1 and the PI3K/PKC signaling pathways in NF-kappaB activation by the HDAC inhibitor apicidin. Biochem Biophys Res Commun 2006; 347: 1088-1093. (Pubitemid 44118225)
58. Kobayashi Y, Ohtsuki M, Murakami T, et al. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. Oncogene 2006; 25: 512-524. (Pubitemid 43164462)
59. Ozaki K, Kosugi M, Baba N, et al. Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. Biochem Biophys Res Commun 2010; 391: 1610-1615.
60. Yu X, Guo ZS, Marcu MG, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002; 94: 504-513. (Pubitemid 34411289)
61. Butler LM, Zhou X, Xu WS, et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 2002; 99: 11700-11705. (Pubitemid 34994462)
62. Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005; 102: 673-678. (Pubitemid 40282724)
63. Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA,. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci U S A 2006; 103: 15540-15545. (Pubitemid 44625628)
64. Cao ZA, Bass KE, Balasubramanian S, et al. CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo. Mol Cancer Ther 2006; 5: 1693-1701. (Pubitemid 44323237)
65. Chou CW, Chen CC,. HDAC inhibition upregulates the expression of angiostatic ADAMTS1. FEBS Lett 2008; 582: 4059-4065.
66. Kim SH, Ahn S, Han JW, et al. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem Biophys Res Commun 2004; 315: 964-970. (Pubitemid 38249397)
67. Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW,. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 2002; 97: 290-296. (Pubitemid 34049018)
68. Mie Lee Y, Kim SH, Kim HS, et al. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 2003; 300: 241-246.
69. Qian DZ, Kato Y, Shabbeer S, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 2006; 12: 634-642. (Pubitemid 43166159)
70. Williams RJ,. Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin Investig Drugs 2001; 10: 1571-1573. (Pubitemid 32717337)
71. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N,. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002; 277: 39858-39866. (Pubitemid 35190971)
72. Fujita N, Sato S, Ishida A, Tsuruo T,. Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J Biol Chem 2002; 277: 10346-10353. (Pubitemid 34968152)
73. Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005; 18: 601-607. (Pubitemid 40726236)
74. Rao R, Fiskus W, Yang Y, et al. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008; 112: 1886-1893.
75. Sato S, Fujita N, Tsuruo T,. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A 2000; 97: 10832-10837.
76. Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO,. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res 2008; 68: 5236-5245.
77. Ammoun S, Cunliffe CH, Allen JC, et al. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol 2010; 12: 834-843.
78. Rong R, Tang X, Gutmann DH, Ye K,. Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A 2004; 101: 18200-18205. (Pubitemid 40054097)
79. Rong R, Ahn JY, Huang H, et al. PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. Nat Neurosci 2003; 6: 1153-1161. (Pubitemid 37346035)
80. Liao Y, Hung MC,. Physiological regulation of Akt activity and stability. Am J Transl Res 2010; 2: 19-42.
81. Okada M, Wang Y, Jang SW, Tang X, Neri LM, Ye K,. Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of merlin. Cancer Res 2009; 69: 4043-4051.
82. Ye K,. Phosphorylation of merlin regulates its stability and tumor suppressive activity. Cell Adh Migr 2007; 1: 196-198.
83. Yaffe MB, Rittinger K, Volinia S, et al. The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 1997; 91: 961-971. (Pubitemid 28027829)
84. Franke TF, Cantley LC,. Apoptosis. A Bad kinase makes good. Nature 1997; 390: 116-117. (Pubitemid 27507959)
85. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR,. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 2000; 20: 8969-8982. (Pubitemid 32245927)
86. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-1321. (Pubitemid 28524494)
87. Kane LP, Shapiro VS, Stokoe D, Weiss A,. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 1999; 9: 601-604.
88. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA,. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-789. (Pubitemid 26004411)
89. Potter CJ, Pedraza LG, Xu T,. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 2002; 4: 658-665. (Pubitemid 34993701)
90. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J,. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 2002; 99: 13571-13576. (Pubitemid 35215423)
91. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC,. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 2002; 10: 151-162. (Pubitemid 34876569)
92. Diehl JA, Cheng M, Roussel MF, Sherr CJ,. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12: 3499-3511. (Pubitemid 28553242)
93. Burgering BM, Medema RH,. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol 2003; 73: 689-701. (Pubitemid 38040447)
94. Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8: 1145-1152. (Pubitemid 35175970)
95. Mamillapalli R, Gavrilova N, Mihaylova VT, et al. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol 2001; 11: 263-267. (Pubitemid 32185329)
96. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB,. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 2002; 277: 5484-5489. (Pubitemid 34968598)
97. Mayo LD, Donner DB,. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 2001; 98: 11598-11603. (Pubitemid 32928774)
98. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC,. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001; 3: 973-982. (Pubitemid 34428742)
99. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC,. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001; 3: 245-252. (Pubitemid 32201319)
100. Kandel ES, Skeen J, Majewski N, et al. Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol 2002; 22: 7831-7841. (Pubitemid 35217294)
101. Altiok S, Batt D, Altiok N, et al. Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells. J Biol Chem 1999; 274: 32274-32278.
102. Shtivelman E, Sussman J, Stokoe D,. A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol 2002; 12: 919-924. (Pubitemid 34689227)
103. Rosato RR, Grant S,. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005; 9: 809-824. (Pubitemid 41131680)
104. Sargeant AM, Rengel RC, Kulp SK, et al. OSU-HDAC42, a Histone Deacetylase Inhibitor, Blocks Prostate Tumor Progression in the Transgenic Adenocarcinoma of the Mouse Prostate Model. Cancer Res 2008; 68: 3999-4009.